Recent approaches in acute lymphoblastic leukemia in adults

Critical Reviews in Oncology/Hematology

Volumn 36, Issue 1, 2000, Pages 49-58

  Hoelzer, Dieter ^a   Gökbuget, Nicola ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukemia; Bone marrow transplantation; Chemotherapy; Immunophenotype; Minimal residual disease; Ph BCR ABL positive ALL; Prognostic factors; Review

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE MACROGOL; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PROTEIN TYROSINE KINASE; RIBOZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PROGNOSIS; REVIEW; RISK FACTOR;

ADULT; BONE MARROW TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; RISK FACTORS;

EID: 0343714608     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00097-4     Document Type: Review

References (53)

1. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004.
2. Lluesma-Gonalons M., Pavlovsky S., Santarelli M.T., et al. Improved results of an intensified therapy in adult acute lymphocytic leukemia. Ann. Oncol. 2:1991;33-39.
3. Ellison R.R., Mick R., Cuttner J., et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by cancer and leukemia group B. J. Clin. Oncol. 9:1991;2002-2015.
4. Cuttner J., Mick R., Budman D.R., et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia. 5:(5):1991;425-431.
5. Linker C.A., Levitt L.J., O'Donnell M., Forman S.J., Ries C.A. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 78:1991;2814-2822.
6. Stryckmans P., de Witte T., Marie J.P., et al. Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 and ALL-3). Leukemia. 6:(Suppl 2):1992;199-203.
7. Bassan R., Battista R., Rohatiner A.Z.S., et al. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period. Leukemia. 6:(Suppl 2):1992;186-190.
8. Hoelzer D., Thiel E., Ludwig W.D. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84), Leukemia 1993;Suppl. 2:130-134.
9. Durrant I.J. Results of Medical Research Council Trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia. Br. J. Haematol. 85:1993;84-92.
10. Fiere D., Lepage E., Sebban C., et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J. Clin. Oncol. 11:(10):1993;1990-2001.
11. Attal M., Blaise D., Marit G., et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood. 86:1995;1619-1628.
12. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 85:1995;2025-2037.
13. Mandelli F., Annino L., Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br. J. Haematol. 92:1996;665-672.
14. Mandelli F., Annino L., Vegna M.L., et al. Adult acute lymphoblastic leukemia (ALL): results of the Gimema ALL 0288 trial. Br. J. Haematol. 93:(S2):1996;144a.
15. Dekker AW, van't Veer MB, Sizoo W, et al. The Dutch Hemato-Oncology Research Group. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. J. Clin. Oncol. 1997;15:476-482.
16. Wernli M, Abt A, Bargetzi M, et al. The Swiss Group of Clinical Cancer Research SAKK. A new therapeutic strategy in adult acute lymphoblastic leukemia intensive induction/consolidation, early transplant, maintenance-type therapy in relapse only. Proc. Am. Soc. Clin. Oncol. 1997;16:6a.
17. Durrant I.J., Prentice H.G., Richards S.M. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Br. J. Haematol. 99:1997;84-92.
18. Ribera JM, Ortega JJ, Oriol A, et al. Members of the PETHEMA Cooperative Group. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter trial (PETHEMA ALL-89). Haematologica 1998;83.
19. Bassan R., Lerede T., Rambaldi A., et al. The role of anthracyclines in adult acute lymphoblastic leukemia. Leukemia. 10:(S2):1996;S58-S61.
20. Todeschini G., Tecchio C., Meneghini V., et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 12:1998;144-149.
21. Douer D., Watkins K., Periclou L.A., Cohen L.J., Avramis V.I. PEG l-asparaginase (PEG-ASNase) containing chemotherapy in untreated acute lymphoblastic leukemia adults. Proc. Am. Soc. Clin. Oncol. 16:1997;30a.
22. Weiss M., Maslak P., Feldman E., et al. Cytarabine with high-dose motixantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J. Clin. Oncol. 14:1996;2480-2485.
23. Hallbook H., Simonsson B., Bjorkholm M., et al. High dose ara-c as upfront therapy for adult patients with acute lymphoblastic leukemia (ALL). Blood. 94:1999;1327a.
24. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 18:2000;547-561.
25. Wiernik P.H., Dutcher J.P., Paietta E., et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia. 7:1993;1236-1241.
26. Daenen S., van Imhoff G.W., van den Berg E., et al. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction: preliminary results on 66 patients. Br. J. Haematol. 100:1998;273-282.
27. Linker C.A., Ries C.A., Damon L.E., Rugo H.S. Intensified and shortened chemotherapy for adult acute lymphoblastic leukemia. Blood. 90:1997;1485a.
28. Cassileth P.A., Andersen J.W., Bennett J.M., et al. Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia. 6:(Suppl. 2P):1992;178-181.
29. Wernli M., Tichelli A., von Fliedner V., et al. Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: a pilot assessment. Br. J. Haematol. 87:1994;39-43.
30. Zhang M.J., Hoelzer D., Horowitz M.M., et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann.Intern.Med. 123:1995;428-431.
31. Fiere D. Long term results of a prospective Belgium French protocol of treatment for adult acute lymphoblastic leukemia (ALL): LALA87 study. Ann. Hematol. 78:1999;32a.
32. Rowe J.M., Richards S., Wiernik P.H., et al. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): early results from the international ALL trial (MRC UKALL/ECOG E2993). Blood. 94:1999;732a.
33. Gorin N.C., Labopin M. Analysis of the Acute Leukemia EBMT Registry: N.C. Gorin on behalf of the ALWT. Bone Marrow Transplant. 19:(Suppl 1):1997;S77.
34. Sierra J., Storer B., Hansen J.A., et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 89:1997;4226-4235.
35. Gökbuget N., Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J. Neuro. Oncol. 38:1998;167-180.
36. Hoelzer D., Arnold R., Freund M., et al. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL). Blood. 94:1999;2926a.
37. Hoelzer D., Thiel E., Löffler H., et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 71:1988;123-131.
38. Griesinger F., Jahn T., Elfers H., et al. Heterogeneity of HRX-FEL fusion transcripts in adult and pediatric t(4;11) ALL. Hiddemann, et al. Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases. 1996;15-21 Springer-Verlag, Berlin Heidelberg.
39. Janssen J.W.G., Ludwig W.-D., Borkhardt A., et al. Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood. 84:1994;3835-3842.
40. Ludwig W.-D., Rieder H., Bartram C.R., et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 92:1998;1898-1909.
41. Hoelzer D., Ludwig W.-D., Thiel E., et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 87:1996;495-508.
42. Thomas D.A., Cortes J., O'Brien S., et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J. Clin. Oncol. 17:1999;2461-2470.
43. Chessells J.M., Hall E., Prentice H.G., Durrant J., Bailey C.C., Richards S.M. The impact of age on outcome in lymphoblastic leukemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 12:1998;463-473.
44. Martin H., Atta J., Zumpe P., et al. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Exp. Hematol. 23:1995;1612-1618.
45. Atta J., Fauth F., Keyser M., et al. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplant. 25:2000;97-104.
46. Campana D., Pui C.-H. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood. 85:1995;1416-1434.
47. Roberts M., Estrov Z., Kitchingman G.R., Zipf T.F. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification of antigen-receptor gene sequences. Leuk. Lymphoma. 20:1996;181-197.
48. Faderl S., Estrov Z., Machida U., et al. Detection of residual disease in cbildhood acute lymphoblastic leukemia. N. Engl. J. Med. 340:1999;152-154.
49. Campana D. Immunophenotypic analysis in the monitoring of minimal residual disease. Rev. Clin. Exp. Hematol. 1:1997;42-56.
50. Brisco M.J., Condon J., Highes E., et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 343:1994;196-200.
51. Brisco M.J., Hughes E., Neoh S.H., et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 87:1996;5251-5256.
52. van Dongen J.J., Seriu T., Panzer-Grümayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet. 352:1998;1731-1738.
53. Cavé H., Van der Werff Ten Bosch J., Suciu S., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 339:1998;591-598.